AFP and hepatocellular carcinoma: In the study by Watanabe, patients with a baseline FIB4 > 4 and post-SVR AFP > 6 ng/dL had one and two-year cumulative HCC incidence rates of 6.1% and 14.4%, respectively, compared with two-year incidence rates of only 0.4% in those with a baseline FIB4 < 4 and post-SVR AFP < 6 ng/dL (p < 0.001) [43].